BIOPHARMA analyzes the U.S. Biopharmaceuticals Market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. The report also analyses the current trends and focus of the U.S. biopharmaceutical market and the challenges faced by the industry. It also provides profiles of the major companies participating in the United States market.
Browse market data tables and in-depth TOC on U.S. Biopharmaceutical Market – Trends, Forecast, Competition & Strategic Analysis (2009 – 2016)
Early buyers will receive 10% customization of reports.
The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. This growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecasted to grow at a compound annual growth rate (CAGR) of 11.2%.
This research report analyzes the U.S. biopharmaceuticals market and its growth factors, with special emphasis on top companies in the field and their product pipeline. While it looks at the overall market size and presents forecast till 2016.
A key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has led to the metamorphosis of the pharmaceutical industry, resulting in the subset industry of biopharmaceuticals. The big players in the pharma industry, including Pfizer, Merck, and Novartis, have been the first few to reap the benefits of investing in biotechnology through both organic as well as inorganic growth mechanisms.
Market forecasts include the biopharmaceuticals currently in the market as well as those projected to enter the market by the end of the forecast period in 2016. Market challenges, drivers, and restraints have also been identified and assessed. Selected late stage pipeline analysis is also included.
This report analyzes the biopharmaceutical industry’s products, features, companies, market size and potential and patent portfolios. The impact of the Medicare and Medicaid policies and individual plan behaviors on the biopharmaceutical industry is also discussed.
• To define and measure the biopharmaceutical market in the U.S.
• To identify the major drivers, restraints, and opportunities in the biopharmaceutical market.
• To identify and analyze comprehensively the biopharmaceutical market structure with respect to the factors influencing market growth and industry-specific challenges.
• To analyze the trends and provide the forecasts for the biopharmaceutical market and its segments with respect to different geographies.
• To identify the major stakeholders in the biopharmaceutical market and draw a competitive landscape.
• To understand the regulatory framework, patient safety and pricing issues of the biopharmaceutical market.
Scope of the report
This section discusses the market definition of U.S. biopharmaceutical market. This section also discusses the way market is segmented and the methodology as well as the assumptions considered for forecasting the revenues for the all the individual product/drug class segments.
This research service covers biopharmaceuticals and their impact on the U.S. healthcare market.
Products included in this study by their market segmentation:
• Gene and Cell therapies, including “Antisense Therapies”
• PEH: Proteins, Enzymes, and Hormones
• Monoclonal Antibodies
• Others: Blood and Allergenic components and others.
Products not included:
• Biosurgical products like tissue grafts and sealants
• Biologics used for diagnostic purposes
• Bionanotechnology drugs
This section discusses the current trends and focus of the U.S. biopharmaceutical market and the challenges faced by the industry. Other sections include market analysis, patent analysis and competitive landscape.
This section provides the company profiles of major companies participating in the U.S. biopharmaceutical market. Company profiles include a brief overview of the company, primary business, strategies followed and developments.
Analyst Briefing Presentation on U.S. Biopharmaceutical Market – Trends, Forecast, Competition & Strategic Analysis (2009 – 2016) to be held on 14 Dec 2010
The CMF practice at MarketsandMarkets is pleased to announce its Analyst Briefing Presentation on U.S. Biopharmaceutical Market – Trends, Forecast, Competition & Strategic Analysis (2009 – 2016) to be held on 14 Dec 2010. The briefing will cover an analysis of trends and current focus of the U.S. biopharmaceutical market and the challenges faced by the industry. The impact of biopharmaceuticals on the U.S. healthcare market will also be discussed during the briefing.
To register for this briefing, please click here
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategic advisory reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.
M&M Banking and Financial Services practice recognizes the challenges that financial institutions face bringing the right products to market. Our reports and consulting practice provide a unique perspective allowing the financial institution to see and experience the best way to achieve their product goals. Through a mix of case studies, primary research, and business modeling we provide a 360° view to identify how you can create, capture, and keep the value of your product and out think the competition.
7557 Rambler road,
Suite 727, Dallas, TX 75231